[Indications and clinical experiences with heparin therapy].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to P Krepler.
Explore the source record for details and available documents.
In 2 groups of patients under treatment with acute lymphatic leukemia and undifferentiated leukemia, apart from the lymphocyte count, a number of immunologic parameters were examined during the various stages of treatment. These parameters were related to the type of chemotherapy as well as the stages of treatment. This paper deals with the values of lymphocyte counts, of gammaglobulin, IgG, IgM and IgA and the results of the DNCB skin-tests, as a parameter for cellular immunity. The determination of gammaglobulin using the acetate sheet electrophoreses, showed no significant change. However a significant reduction of the IgG was shown during the periods of prophylactic reinduction with Vincristin in the Pinkel VII scheme. IgM quantities were significantly raised in the initial stage before treatment and in all periodes of treatment both in the Pinkel VII group and in an earlier therapeutic group with methotrexate two weekly and Vincristin pulses every 6 weeks. IgA was raised in both groups before treatment but significantly reduced during maintenance and reinduction phases. About 50% of the P VII cases had negative DNCB skintests during maintenance therapy, while all long term survivors in the earlier methotrexate treatment group had positive skintests. The 2 following papers deal with the results of PHA stimulation and the B and T cell determinations.
Clinical experience is reported with bis-dioxopiperazine propane (ICRF 159) in 20 children with acute leukaemia in relapse. They were resistant to most of the generally used cytotoxic drugs. Despite the unfavourable selection of cases, two complete and seven incomplete remissions lasting from 1 to 6 months were obtained.
Drawing on unselected case histories of 650 children (2-12 months) the authors study the frequency of dysplasia of the hip from the orthopedic and pediatric points of view. The X-ray findings for dysplasia are classified in terms of different degrees of severity and compared with clinically demonstrable symptoms of dysplasia. This comparison showed 88 (13.5%) cases of dysplasia diagnosed on the basis of X-ray findings; 32 (4.9%) of these presented no clinical symptoms whatever. This would mean that more than one third of all cases of dysplasia are not detected clinically when there is only a single examination. Even when the under-three-months age group is excluded, we must still assume 3.3% clinically inconspicuous cases of dysplasia. This situation makes for considerable difficulty in diagnosing dysplasia of the hip. In view of well-known delayed effects of this disease, the authors urge that it be diagnosed as throughly and comprehensively as possible. As an improved approach to dealing with this problem, they recommend regular pediatric examinations plus obligatory orthopedic check-ups of every infant and X-ray examination wherever there is the slightest suspicion of congenital dysplasia of the hip.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The principles according to modern views and practical needs of classification of acute leukemia are discussed on the basis of morphological properties of the leukemic cells after panoptic staining and of their cytochemical reactions. This form of classification gives some indications for the choice of treatment and for the prognosis. It is also the permission for the evaluation of therapeutic results, as are the other factors relevant for the prognosis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.